University of California, Los Angeles Neuro-Oncology : UCLA Neuro-Oncology: Research Publications

Contact Us \| Directions \| Referring a Patient
A leading comprehensive brain tumor program, using molecular diagnostic, gene expression analysis, cutting edge clinical trials and advanced medical informatics to customize treatment plans for cancer patients.

Home > UCLA Neuro-Oncology: Research Publications

UCLA Neuro-Oncology: Research Publications

A listing of research findings by UCLA Neuro-Oncology and in cooperation with their research partners.


Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. Cancer Res PMID: 19934335 ; 69(23):9133-40	Bevacizumab for recurrent ependymoma. Neurology 73(20):1677-80.PMID: 19917990	Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. (28):4733-40; PMID: 19720927	Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res PMID: 19690143 ; 69(17):6889-98

Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. J Neurooncology PMID: 19655089	The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A PMID: 19625624	Striking the balance between PTEN and PDK1: it all depends on the cell context. Genes Dev PMID: 19651981	Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell PMID: 19573811 ; 16(1):44-54.

Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics PMID:19561256 ; 252(1):182-9.	Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 252(1):182-9.PMID: 19561256	Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncology PMID: 19562255	The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A. 106(23):9435-40 PMID: 19478061

Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neurooncology PMID: 19468690	Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells (4):980-7. PMID: 19353526	Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 7;72(14):1217-22.	A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol. 183-9

A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neurooncol. 91(2):175-82	Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26(34):5610-7	A tool for improving the longitudinal imaging characterization for neuro-oncology cases. AMIA Annu Symp Proc. 712-6.	Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics

Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med 359(5):539-41	(18)F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: Initial experience. Eur J Radiol. PMID: 18511228	Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol PMID: 18436627	Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncology PMID: 18356283

Time course of imaging changes of GBM during extended bevacizumab treatment J Neurooncol. PMID: 18389177	Phase II Pilot Study of Bevacizumab in Combination With Temozolomide and Regional Radiation Therapy for Up-Front Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Interim Analysis of Safety and Tolerability. Int J Radiat Oncol Biol Phys PMID: 18355978	Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. PMID: 18215105	Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics

Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics	Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res PMID: 18223223	Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res PMID: 18223223	Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res PMID: 18094423

Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma Proc Natl Acad Sci PMID: 18077431	Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study Clin Cancer Res PMID: 18056194	Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study J Clin Oncol PMID: 17947718	18F-FDOPA kinetics in brain tumors. J Nucl Med 1651-61. PMID: 17873130

Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. J Neurosci Res	Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother Pharmacol	Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2 Clin Cancer Res PMID: 17473188 (9):2592-8.	(18)F-fluorothymidine kinetics of malignant brain tumors. Eur J Nucl Med Mol Imaging. PMID: 17295039

High-throughput oncogene mutation profiling in human cancer. Nat Genet PMID: 17293865	PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res PMID: 17255257	Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain. PLoS Medicine PMID: 17177598 ; 3(12):e485	Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci 103(46):17402-7; PMID: 17090670

A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme J Neurooncol PMID: 17031561	Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res. PMID: 16966431 ;4(9):607-19.	Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12(16):4899-907. PMID: 16914578	Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-Deficient and PTEN-Intact Glioblastoma Cells. Cancer Res. 66(16): 7864-9 PMID: 16912159

Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 24(22):3651-6. PMID: 16877733	18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 47(6):904-11. PMID: 16741298	Using molecular information to guide brain tumor therapy. Nat Clin Pract Neurol 232-3. PMID: 16932555	MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66(8):1258-60. PMID: 16636248

Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Research 66(1):159-67. PMID: 16397228	Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 353(19):2012-24. N Engl J Med. 2006 Feb 23;354(8):884. PMID: 16282176	MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 26(10):2466-74. PMID: 16286386	Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study J Clin Oncol. 23(27):6647-56. PMID: 16170172

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 1;11(15):5515-25. PMID: 16061868	Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 23(4):357-61. PMID: 16012795	Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J Biol Chem. 22;280(29):26953-64. Epub 2005 May 20. PMID: 15908427	Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 46(6):945-52. PMID: 15937304

Robustness of gene expression profiling in glioma specimen samplings and derived cell lines. Brain Res Mol 20;136(1-2):99-103. PMID: 15893592	EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells. Cancer Biol Ther. 3(12):1243-9. Epub 2004 Dec 14. PMID: 15611621	Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol. 1;22(21):4282-9. PMID: 15514370	Brain tumor treatment: chemotherapy and other new developments. Semin Oncol Nurs. 20(4):260-72. Review. PMID: 15612602

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs. 22(4):427-35. PMID: 15292713	DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci. 5(10):782-92. Review. PMID: 15378038	Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 15;64(18):6503-10. PMID: 15374961	Prediction of neurocognitive outcome in adult brain tumor patients. J Neurooncol. 67(1-2):245-53. PMID: 15072475

p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene. 12;23(6):1283-90. PMID: 14961077	Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncolgy 6(1):44-54. PMID: 14769140	Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Lab Invest 84(1):8-20. PMID: 14631378	Oncodiagnosis panel: 2002. Patient's symptoms not related to the lesion seen in the MR images. Radiographics. 23(6):1591-611. PMID: 14635615

Oncodiagnosis panel: 2002. Metastatic NSCLC. Radiographics. 23(6):1591-611 PMID: 14628846	Oncodiagnosis panel: 2002. Patient's symptoms not related to the lesion seen in the MR images. Radiographics. 23(6):1591-611. PMID: 14635615	Gene expression profiling identifies molecular subtypes of gliomas. Oncogene. 31;22(31):4918-23. PMID: 12894235	Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 15;21(12):2305-11. PMID: 12805331

Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 1;63(11):2742-6. PMID: 12782577	Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 1;97(9 Suppl):2381-6. PMID: 12712460	Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol Ther. 2(3):242-7. Review. PMID: 12878856	Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene. 17;22(15):2361-73. PMID: 12700671

Targeted molecular therapy of GBM. Brain Pathol. 13(1):52-61. Review. PMID: 12580545	Novel methodology for the archiving and interactive reading of clinical magnetic resonance spectroscopic imaging. Magn Reson Med. 48(3):411-8. PMID: 12210904	Predicting major depression in brain tumor patients. Psychooncology. 11(3):230-8. PMID: 12112483	Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Am J Clin Oncol 204-8. PMID: 11943904

A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study Neuro-oncology 4(2):109-14. PMID: 11916502	Mapping therapeutic response in a patient with malignant glioma. J Comput Assist Tomogr 25(4):529-36. PMID: 11473181	Intraarterial chemotherapy for brain tumors by using a spatial dose fractionation algorithm and pulsatile delivery. Radiology. 218(3):724-32. PMID: 11230646	Tracking tumor growth rates in patients with malignant gliomas: a test of two algorithms. AJNR Am J Neuroradio 22(1):73-82. PMID: 11158891

Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium. Neuro-Oncology 3(1):46-54. PMID: 11305417	Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol 50(3):215-26. PMID: 11263501	Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy. AJNR Am J Neuroradiol 21(3):471-8. PMID: 10730637	Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas. Neurosurgery 44(2):270-8; discussion 278-9. PMID: 9932880

Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma. Magn Reson Med 41(1):2-7. PMID: 10025604	Topographical and temporal specificity of human intraoperative optical intrinsic signals. Neuroreport. 3;9(11):2557-63. PMID: 9721932	Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow. J Neurooncol 35(2):121-31. PMID: 9266448	Prolonged treatment with biologic agents for malignant glioma: a case study with high dose tamoxifen. J Neurooncol 35(1):39-45. PMID: 9266439

Pharmacological blood-brain barrier modification for selective drug delivery. J Neurooncol 26(2):125-32. Review. PMID: 8787854	Novel brainstem syndrome associated with prostate carcinoma. Neurology 43(12):2591-6. PMID: 8255462	Topographic mapping of somatosensory evoked potentials helps identify motor cortex more quickly in the operating room. Brain Topogr. 5(1):53-8. PMID: 1463660

* Published: Wednesday, March 10, 2010 : 3:53:37 PM PT

All Information content hearof is designed for educational purposes only and is not for the purpose of rendering medical advice or professional services. The information provided should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. Any specific questions you may have regarding an individual's medical condition should be directed to the individual's primary care physician or other attending physician. In addition, if you have or suspect you may have a health problem, you should consult your health care provider.

Portions Copyright (Search, Chart, Content Publishing Tools, Photography, Provider^IQ) 1998-2010 SiliconMED North America

Provider^IQ is a registered trademark of SiliconMED North America and used by permission.

[Content Published:3/10/2010 3:53:37 PM PST]